Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daptomycin is inhibited by pulmonary surfactant 160 and thus is contraindicated in the treatment of S aureus pneumonia acquired via the aspiration route.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Pulmonary surfactant: functions and molecular composition
Goerke, J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00060-x · Cited by 724 · cited 3×
“pulmonary surfactant is different from that of most eukaryotic membranes; it primarily contains PC and only low levels of cholesterol and sphingolipids [3].”
BackgroundInfluentialCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656 · cited 2×
“molecular synthesis, and cell death [7].”
BackgroundSelf-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundCarpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358 · cited 1×
“class of antibiotics, the lipopeptides [6].”
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297 · cited 3×
“Daptomycin is inserted into the membrane of gram-positive bacteria and artificial lipid vesicles [7, 15, 16].”
BackgroundPenetration of Antibiotics into Respiratory Secretions
Pennington, J. E. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.67 · Cited by 192
Extraction, Characterization, and Cellular Localization of the Lipids of Staphylococcus aureus
White, D. C., & Frerman, F. E. (1967) · Journal of Bacteriology · doi:10.1128/jb.94.6.1854-1867.1967 · Cited by 184 · cited 1×
“Surfactant is also ∼10% PG, a prominent component of the gram-positive plasma membrane [18].”
BackgroundSakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundSelf-citation
Cited by
Items 201–300 of 548
Yang, Z., Liu, Y., Ahn, J., Qiao, Z., Endres, J. L., Gautam, N., Huang, Y., Li, J., Zheng, J., Alnouti, Y., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.017 · Cited by 29
Ellison, R. T., & Donowitz, G. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00069-2 · Cited by 34
“One agent, daptomycin, has been shown to bind to pulmonary surfactant, thereby decreasing its efficacy in treating pneumonia.(296) Pharmacokinetics and pharmacodynamics are important in defining appropriate antibiotic dosing.”
Libert, N., Batjom, E., Cirodde, A., de Rudnicki, S., Grasser, L., Borne, M., & Brinquin, L. (2008) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2008.10.008 · Cited by 26
Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients.
Imaz, A., Pujol, M., Barragán, P., Domínguez, M. Á., Tiraboschi, J. M., & Podzamczer, D. (2010) · PubMed · Cited by 26
Daptomycin use in neutropenic patients with documented gram-positive infections
Rolston, K. V. I., Besece, D., Lamp, K. C., Yoon, M., McConnell, S. A., & White, P. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1947-8 · Cited by 25
“A potential drawback of daptomycin is that pulmonary surfactant prevents daptomycin’s antibacterial activity [42].”
BackgroundBacterial Pneumonia and Lung Abscess
Torres, A., Menéndez, R., & Wunderink, R. G. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00033-6 · Cited by 33
“treatment of pneumonia, because it binds to and is inactivated by pulmonary surfactant.(171)”
BackgroundDaptomycin-induced Acute Eosinophilic Pneumonia
Kumar, S., Sánchez, I. A., & Rajagopalan, N. (2018) · Cureus · doi:10.7759/cureus.2899 · Cited by 25
“The precise mechanism for daptomycin-induced lung injury is unknown but is believed to be related to daptomycin binding to pulmonary surfactant culminating in epithelial injury [2].”
BackgroundSamura, M., Kitahiro, Y., Tashiro, S., Moriyama, H., Hamamura, Y., Takahata, I., Kawabe, R., Enoki, Y., Taguchi, K., Takesue, Y., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040714 · Cited by 27
“Seventh, DAP has been shown to be inactivated by pulmonary surfactants [48] and is, therefore, not recommended for the treatment of pneumonia [6].”
BackgroundDaptomycin use in patients with cancer and neutropenia: data from a retrospective registry.
Rolston, K. V. I., McConnell, S. A., Brown, J. E., & Lamp, K. C. (2010) · PubMed · Cited by 27
Page, M. G. P. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.4.511 · Cited by 25
“The new agents may have limitations in tolerability [1-3] or efficacy in some clinical settings [4,5] .”
BackgroundValente, L. G., Federer, L., Iten, M., Grandgirard, D., Leib, S. L., Jakob, S. M., Hænggi, M., Cameron, D. R., Que, Y., & Prazak, J. (2021) · BMC Research Notes · doi:10.1186/s13104-021-05796-1 · Cited by 25
The Chiral Target of Daptomycin Is the 2 R ,2′ S Stereoisomer of Phosphatidylglycerol
Moreira, R., & Taylor, S. D. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202114858 · Cited by 24
Kassab, G., Tovar, J. S. D., Souza, L. M. P., Costa, R. K. M., Silva, R. S., Pimentel, A. S., Kurachi, C., & Bagnato, V. S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123564119 · Cited by 24
Dallow, J., Otterson, L. G., Huband, M. D., Krause, K. M., & Nichols, W. W. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.07.023 · Cited by 24
In Vivo Pharmacodynamics of New Lipopeptide MX-2401
Craig, W. A., Andes, D. R., & Stamstad, T. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-10 · Cited by 24
“In contrast, no detectable reduction of the bacterial counts was observed by daptomycin in this model (20).”
BackgroundResultSchefold, J. C., Esposito, F., Storm, C., Heuck, D., Krüger, A., Jörres, A., Witte, W., & Hasper, D. (2007) · Journal of Medical Case Reports · doi:10.1186/1752-1947-1-165 · Cited by 24
Schneider‐Futschik, E. K., Paulin, O. K. A., Hoyer, D., Roberts, K. D., Ziogas, J., Baker, M. A., Karas, J. A., Li, J., & Velkov, T. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00238 · Cited by 24
Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection
Burgos, R. M., Biagi, M. J., Rodvold, K. A., & Danziger, L. H. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1511702 · Cited by 24
“baumannii) were later studied in the presence of varying concentrations of bovine-derived surfactant to determine if M/V activity was affected by lung surfactant, as has been previously described for agents such as daptomycin [39,40].”
BackgroundMoreira, R., Wolfe, J., & Taylor, S. D. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02504f · Cited by 24
Basarab, G. S., Ghorpade, S. R., Gibhard, L., Mueller, R. W., Njoroge, M., Peton, N., Govender, P., Massoudi, L. M., Robertson, G. T., Lenaerts, A. J. M., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02192-21 · Cited by 24
“There was minimal or no shift in MIC values in the presence of DPPC, the principle (;80%) component of lung surfactant, which might have accounted for decreased susceptibility if there was a tight interaction (14).”
BackgroundChapter 20 Biosynthesis and Genetic Engineering of Lipopeptides in Streptomyces roseosporus
Baltz, R. H. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)04820-4 · Cited by 24
Investigational treatments for postoperative surgical site infections
Poulakou, G., & Giamarellou, H. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.137 · Cited by 24
“Pulmonary infections are not within daptomycin’s indications because the drug is inactivated by pulmonary surfactants [51].”
BackgroundNowakowska, J., Griesser, H. J., Textor, M., Landmann, R. M., & Khanna, N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-12 · Cited by 24
“This is well exemplified by daptomycin, which undergoes organ-specific inhibition by pulmonary surfactants (45).”
BackgroundAdvances in Antibacterial Therapy Against Emerging Bacterial Pathogens
Pournaras, S., Iosifidis, Ε., & Roilides, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.03.007 · Cited by 23
He, Y. Q., Li, J., Yin, N., Herradura, P. S., Martel, L., Zhang, Y., Pearson, A. L., Kulkarni, V., Mascio, C. T. M., Howland, K., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.013 · Cited by 23
Self-citationPolyfunctional Antibiotics Affecting Bacterial Membrane Dynamics
Nelson, M. L., Grier, M. C., Barbaro, S., & Ismail, M. (2009) · Anti-Infective Agents · doi:10.2174/187152109787047779 · Cited by 23
Chitnis, S., Katara, G., Hemvani, N., Pareek, S., & Chitnis, D. S. (2013) · PubMed Central · Cited by 23
Antibacterial drug development program successes and failures: a pharmacometric explanation
Ambrose, P. G. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.06.002 · Cited by 23
“Instead, the pivotal animal study was conducted post-mortem [18].”
BackgroundHetem, D. J., Rooijakkers, S. H. M., & Ekkelenkamp, M. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00176-3 · Cited by 38
Chen, D., Po, K. H. L., Blasco, P., Chen, S., & Li, X. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01544 · Cited by 23
New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus
Bouza, E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03091.x · Cited by 29
Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria
Kinney, K. K. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181e99aa4 · Cited by 25
Daptomycin compared to standard therapy for the treatment of native valve endocarditis
Kanafani, Z. A., Boucher, H. W., Fowler, V. G., Cabell, C. H., Hoen, B., Miró, J. M., Lalani, T., Vigliani, G. A., Campion, M., Corey, R. G., et al. (2010) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2009.07.015 · Cited by 23
“Final diagnosis, n (%) uRIE 6 (21) 4 (16)”
Abel, K. M., Agnew, E., Amos, J., Armstrong, N., Armstrong-James, D. P. H., Ashfield, T., Aston, S., Baillie, J. K., Baldwin, S., Barlow, G. D., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00003-x · Cited by 22
“…MDR or XDR Pseudomonas aeruginosa ), 22 scarce activity in relevant organs such as the lung (eg, insuf fi cient ef fi cacy of daptomycin for pneumonia), 23 or evidence of activity of novel agents against emergent pathogens and diseases (eg, fosmanogepix for fungal meningitis caused by Fusarium spp).”
BackgroundDaptomycin-induced acute eosinophilic pneumonia
Patel, J. J., Antony, A., Herrera, M., & Lipchik, R. J. (2016) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc2016.0413.174 · Cited by 22
“In vitro experiments using bovine-derived surfactant have demonstrated that daptomycin binds to surfactant molecules and that its bactericidal activity rapidly drops with even low concentrations of surfactant.(2) It is likely then that the drug accumulates in surfactant-lined alveoli, resulting in activation of alveol…”
BackgroundColquhoun, J. M., Wozniak, R. A. F., & Dunman, P. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143033 · Cited by 22
“These results support those of Silverman and colleagues who found surfactant lipid aggregates inhibit daptomycin’s antibacterial activity and likely contribute to the agent’s limited therapeutic efficacy in treating patients with community acquired pneumonia [17].”
BackgroundResultTelles, J. P., Cieslinski, J., Gasparetto, J., & Tuon, F. F. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1627872 · Cited by 22
Daptomycin: Physicochemical, Analytical, and Pharmacological Properties
Tótoli, E. G., Garg, S., & Salgado, H. R. N. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000222 · Cited by 26
“Daptomycin is not significantly absorbed after oral administration(11,34) and is inhibited by pulmonary surfactants, limiting its use by these routes of administration.(42)”
BackgroundChang, J. H. T., Tasellari, A., Wagner, J. L., & Scheetz, M. H. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2275663 · Cited by 22
Bamberger, D. M. (2007) · PubMed Central · Cited by 25
Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
Das, S., Zhou, D., Nichols, W. W., Townsend, A., Newell, P., & Li, J. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02804-z · Cited by 22
Bakthavatchalam, Y. D., Rao, S. V., Isaac, B. T. J., Abi Manesh, S., Nambi, S., Swaminathan, S., Nagvekar, V., Nangia, V., John, P. V., & Veeraraghavan, B. (2019) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_20_34 · Cited by 21
Schaad, H. J., Bento, M., Lew, D. P., & Vaudaux, P. E. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-74 · Cited by 21
“aureus infections [12,21-29] in various deep-seated compartments though minimizing skeletal muscle side-effects [30,31].”
BackgroundPrinciples of Anti-infective Therapy
Pillai, S. K., Eliopoulos, G. M., & Moellering, R. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00018-7 · Cited by 26
Clinical Approach to Antibiotic Failure
Schlossberg, D. (2006) · Medical Clinics of North America · doi:10.1016/j.mcna.2006.07.004 · Cited by 21
Ultrasound‐Mediated Antibiotic Delivery to In Vivo Biofilm Infections: A Review
Liu, J. D., Treeck, K. E. V., Marston, W. A., Papadopoulou, V., & Rowe, S. E. (2024) · ChemBioChem · doi:10.1002/cbic.202400181 · Cited by 20
Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery
Bionda, N., & Čudić, P. (2011) · Croatica Chemica Acta · doi:10.5562/cca1819 · Cited by 20
Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections
Pea, F., & Viale, P. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.2.255 · Cited by 20
Pharmacotherapy for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia
Segarra‐Newnham, M., & Church, T. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r370 · Cited by 20
Ambrose, P. G. (2008) · Clinical Infectious Diseases · doi:10.1086/591427 · Cited by 20
“tomycin in vitro MIC values increasing 100-fold [14].”
BackgroundThe antimicrobial effect of colistin methanesulfonate on Mycobacterium tuberculosis in vitro
van Breda, S. V., Buys, A. V., Apostolides, Z., Nardell, E. A., & Stoltz, A. C. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.05.005 · Cited by 19
“, [31].”
Alemayehu, D., Quinn, J. P., Cook, J., Kunkel, M. J., & Knirsch, C. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis503 · Cited by 20
“Interestingly, preclinical tests have been developed that are reasonably predictive of the loss of drug effect [22].”
BackgroundHarada, Y., Yanagihara, K., Yamada, K., Migiyama, Y., Nagaoka, K., Morinaga, Y., Nakamura, S., Imamura, Y., Hasegawa, H., Miyazaki, T., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02331-12 · Cited by 19
“For the treatment of MRSA-related lung infections, including pneumonia, daptomycin is not recommended because it is inactivated by the lung surfactant (7).”
BackgroundTreatment ofStaphylococcus aureusinfections: new issues, emerging therapies and future directions
Bishop, E. J., & Howden, B. P. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.1.1 · Cited by 24
Inhalable Gene Therapy and the Lung Surfactant Problem
Kassab, G., Doran, K., Mo, Y., & Zheng, G. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03547 · Cited by 18
Rether, C., Conen, A., Grossenbacher, M., & Albrich, W. C. (2011) · Infection · doi:10.1007/s15010-011-0148-y · Cited by 18
“The lipophilic molecule daptomycin interacts calcium-dependently with both bacterial membranes and pulmonary surfactant; insertion into the surfactant is an irreversible process which results in its sequestration, rendering daptomycin inactive and therefore unsuitable for treating pneumonia [ 3 ].”
BackgroundTreatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections in Pediatrics
Newland, J. G., & Kearns, G. L. (2008) · Pediatric Drugs · doi:10.2165/0148581-200810060-00004 · Cited by 19
Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children
Tamma, P. D., & Hsu, A. J. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000115 · Cited by 18
Identification of 5,6-dihydroimidazo[2,1-b]thiazoles as a new class of antimicrobial agents
Li, Y., Bionda, N., Fleeman, R. M., Wang, H., Ozawa, A., Houghten, R. A., & Shaw, L. N. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.027 · Cited by 21
Avdic, E., & Cosgrove, S. E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1463 · Cited by 23
“It is important to note that daptomycin should not be used for the treatment of pneumonia, including pneumonia caused by CA-MRSA, because it is inactivated by pulmonary surfactant [70] ; however, it can be considered an alternative to vancomycin in severe CA-MRSA skin and skin structure or endovascular infections.”
BackgroundNewer developments in the treatment of Gram-positive infections
Koomanachai, P., Crandon, J. L., & Nicolau, D. P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903357491 · Cited by 18
“Daptomycin’s antimicrobial activity is disturbed by pulmonary surfactant and is not recommended for the treatment of pneumonia [65].”
BackgroundRubinstein, E., Corey, G. R., Stryjewski, M. E., & Kanafani, Z. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.633511 · Cited by 17
“In Phase III trials, daptomycin proved inferior to ceftriaxone for the treatment of community-acquired pneumonia (CAP) [38], probably due to inactivation by pulmonary surfactant [39].”
BackgroundJohnson, A. P. (2006) · Future Microbiology · doi:10.2217/17460913.1.3.255 · Cited by 17
Current challenges in treating MRSA: what are the options?
Ratnaraja, N., & Hawkey, P. M. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.601 · Cited by 25
Scaglione, F. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.011 · Cited by 17
“in trials of community-acquired pneumonia and it has subsequently been shown that daptomycin is inactivated by surfactant, rendering it unable to kill bacteria in the alveoli [59,60].”
BackgroundBasabe-Burgos, O., Ahlström, J. Z., Stichtenoth, G., Curstedt, T., Bergman, P., Johansson, J., & Rising, A. (2018) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2018.1468 · Cited by 17
“(10) Instillation of poractant alfa alone did not affect the number of CFUs in the lungs (Fig.”
Mongkolrattanothai, K., & Daum, R. S. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0013-1 · Cited by 19
“The explanation may lie in the interaction in vitro of daptomycin with pulmonary surfactant, resulting in inhibition of antibacterial activity [ 62 ].”
BackgroundYazaki, M., Oami, T., Nakanishi, K., Hase, R., & Watanabe, H. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.02.006 · Cited by 26
Taylor, S. D., & Moreira, R. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.04.003 · Cited by 16
Burgin, D. J., Liu, R., Hsieh, R. C., Heinzinger, L. R., & Otto, M. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040015 · Cited by 21
“The use of daptomycin is inappropriate in patients with MRSA bacteremia secondary to pneumonia, as daptomycin is inactivated by the PG content of pulmonary surfactant [41].”
BackgroundGomez, E., Jafary, A., & Dever, L. L. (2010) · Microbial Drug Resistance · doi:10.1089/mdr.2010.0001 · Cited by 16
“Treatment of gram-positive bacterial lung infections with daptomycin has resulted in clinical failure—most likely due to binding of daptomycin to lung surfactant, resulting in impaired antibacterial action.(8,18) Clinical success has been reported with daptomycin in a subset of patients with septic pulmonary emboli (S…”
Total Synthesis of A54145 Factor D
Kralt, B., Moreira, R., Palmer, M., & Taylor, S. D. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b01938 · Cited by 16
Therapeutic Options for Infections Due to vanB Genotype Vancomycin-Resistant Enterococci
Riccardi, N., Monticelli, J., Antonello, R. M., Lallo, G. D., Frezza, D., Luzzati, R., & Bella, S. D. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0171 · Cited by 19
“43 Linezolid.”
Treatment of MRSA infections in India: Clinical insights from a Delphi analysis
Singhal, T., Rodrigues, C. S., Soman, R. N., Wattal, C., Swaminathan, S., Nambi, S., Talwar, D., Singh, R. K., & Todi, S. K. (2021) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2021.11.005 · Cited by 19
Impact of Community-Associated Methicillin Resistant Staphylococcus aureus on HIV-Infected Patients
Cole, J., & Popovich, K. J. (2013) · Current HIV/AIDS Reports · doi:10.1007/s11904-013-0161-0 · Cited by 21
“Furthermore, daptomycin has poor activity in lung tissues and therefore should not be used in the treatment of pneumonia [74].”
BackgroundMoreira, R., & Taylor, S. D. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b03458 · Cited by 16
Lai, H., Woolner, V. H., Little, R. F., Woolly, E. F., Keyzers, R. A., & Owen, J. G. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410286 · Cited by 15
Moore, J. N., Poon, L., Pahwa, S., Bensman, T. J., Wei, X., Danielsen, Z. Y., & Jang, S. H. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad114 · Cited by 17
A Tick Antivirulence Protein Potentiates Antibiotics against Staphylococcus aureus
Abraham, N. M., Liu, L., Jutras, B. L., Murfin, K. E., Acar, A., Yarovinsky, T. O., Sutton, E., Heisig, M., Jacobs, C., & Fikrig, E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-17 · Cited by 16
“aureus, the most common Grampositive pathogens in community-acquired pneumonia (40, 41).”
BackgroundYamashita, Y., Nagaoka, K., Kimura, H., Suzuki, M., Konno, S., Fukumoto, T., Akizawa, K., Kaku, N., Morinaga, Y., & Yanagihara, K. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00149-19 · Cited by 16
“As a comparison, we also investigated the effect of VCM and DAP; the former is a first-choice drug against MRSA-NP, whereas the latter is less effective due to inactivation by alveolar surfactant (21).”
MethodDaum, R. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00115-8 · Cited by 16
Daptomycin-Associated Eosinophilic Pneumonia in Two Patients with Prosthetic Joint Infection
Yusuf, E., Perrottet, N., Orasch, C., Borens, O., & Trampuž, A. (2014) · Surgical Infections · doi:10.1089/sur.2013.200 · Cited by 14
“One hypothesis is that interaction between daptomycin and surfactant, as shown in vitro [10], might lead to a cascade that causes eosinophil accumulation in the lungs.”
Infections broncho-pulmonaires à Staphylococcus aureus
Valour, F., Chebib, N., Gillet, Y., Reix, P., Laurent, F. J., Chidiac, C., & Ferry, T. (2013) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2013.08.004 · Cited by 17
“Enfin, la daptomycine, lipoglycopeptide utilisé de plus en plus en alternative à la vancomycine est inactivé par le surfactant pulmonaire et ne doit pas être utilisé dans les infections broncho-pulmonaires à SARM, sauf si l’atteinte pulmonaire survient au cours d’une endocardite du cœur droit [82].”
BackgroundGu, J.-Q., Alexander, D. C., Rock, J. L., Brian, P., Chu, M., & Baltz, R. H. (2010) · The Journal of Antibiotics · doi:10.1038/ja.2010.140 · Cited by 14
Myopathy and Eosinophilic Pneumonia Coincidentally Induced by Treatment with Daptomycin
Hagiya, H., Hasegawa, K., Asano, K., Terasaka, T., Kimura, K., Nada, T., Nakamura, E., Waseda, K., Hanayama, Y., & Otsuka, F. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3397 · Cited by 14
“It is well known that the long-term administration of DAP results in the recruitment of T-helper 2 lymphocytes and subsequent release of interleukin-5, which induces the migration of eosinophils (27), thereby causing cellular and/or epithelial damage (8, 17, 28).”
BackgroundCrass, R. L., Powell, K., & Huang, A. M. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.09.004 · Cited by 14
Swift, S. M., Sauve, K., Cassino, C., & Schuch, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02723-20 · Cited by 14
“which then precludes insertion into the membrane of target Gram-positive bacteria (23);”
BackgroundInfluentialMichaeli, J., Mandel, S., Maximov, S., Zazoun, J., Savoia, P., Kothari, N., Valmont, T., Ferrari, L., Duncan, L. R., Hawser, S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11091201 · Cited by 14
“5% (v/v) BPS (data not shown; as a reference, see [25]).”
BackgroundThomsen, I. P., & Creech, C. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00115-4 · Cited by 15
Erturan, G., Holme, H., Smith, R., Dodds, R., & Iyer, S. (2012) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2012.03.014 · Cited by 14
New Antimicrobial Molecules and New Antibiotic Strategies
de Castro, F. R., Naranjo, O. R., Marco, J., & Violán, J. S. (2009) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0029-1202935 · Cited by 14
Lowell, G. S., & Daum, R. S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7020-3468-8.50121-8 · Cited by 15
Management of Gram-positive bacteraemia
Uçkay, İ., Harbarth, S., & Pittet, D. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1bedd · Cited by 14
Zhou, F., Liu, C., Mao, Z., Yang, M., Kang, H., Liu, H., Pan, L., Hu, J., & Luo, J. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s115175 · Cited by 14
“32 However, because of an interaction between daptomycin and a pulmonary surfactant identified in vitro, 33 daptomycin is not prescribed for the treatment of pneumonia.”
Barman, T. K., Kumar, M., Mathur, T., Namba, E., Singh, D., Chaira, T., Kurosaka, Y., Yamada, M., Upadhyay, D. J., & Masuda, N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02556-17 · Cited by 14
“a pulmonary surfactant significantly impairs the antibacterial activities of many standard antibiotics, such as moxifloxacin, colistin, and daptomycin (30, 31).”
BackgroundMorrisette, T., Lagnf, A. M., Alosaimy, S., & Rybak, M. J. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03941-5 · Cited by 14
US FDA-Approved Antibiotics During the 21st Century
Hori, T., Owusu, Y., & Sun, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00144-0 · Cited by 14
Pneumonia Caused by Staphylococcus aureus
Haessler, S., & Brown, R. B. (2009) · Current Respiratory Medicine Reviews · doi:10.2174/157339809787354056 · Cited by 14
Total Synthesis of Analogs of A54145D and A54145A 1 for Structure–Activity Relationship Studies
Kralt, B., Moreira, R., Palmer, M., & Taylor, S. D. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02922 · Cited by 13
Novel FtsZ inhibitor with potent activity against Staphylococcus aureus
Kumar, M., Mathur, T., Barman, T. K., Chaira, T., Kumar, R., Joshi, V., Pandya, M., Sharma, L., Fujii, K., Bandgar, M. D., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab270 · Cited by 13
Metadata
- Authors
- Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J.
- Affiliations
- Cubist Pharmaceuticals (United States) (US)
- Corresponding author
- Silverman, Jared A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 2149-2152
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108525727
- Cited by
- 541
- References
- 18
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 25 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 18 · 2019: 20 · 2018: 24 · 2017: 24 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 28
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Keywords
- daptomycin, pulmonary surfactant, antibiotic inhibition, lipopeptide antibiotics, Staphylococcus aureus, Streptococcus pneumoniae, community-acquired pneumonia, inhalational anthrax, antibiotic-drug interactions
- MeSH terms
- Animals, Anti-Bacterial Agents, Lung, Microbial Sensitivity Tests, Pneumococcal Infections, Pulmonary Surfactants, Staphylococcal Infections, Daptomycin, Pneumonia, Bacterial, Drug Resistance, Bacterial, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.